Michal Kascak
Overview
Explore the profile of Michal Kascak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Venglar O, Radova E, Zihala D, Tvrda I, Kubala V, Kutejova K, et al.
Am J Hematol
. 2025 Jan;
100(4):704-707.
PMID: 39812365
No abstract available.
2.
Susol O, Susolova B, Klempir O, Navratil M, Gumulec J, Koristek Z, et al.
Cancer Med
. 2024 Dec;
13(24):e70503.
PMID: 39711119
Aims: To evaluate antibody response to mRNA vaccine, identify subgroups with poor response and to determine long-term antibody durability in hematological patients. Materials And Methods: We have vaccinated 292 patients...
3.
Dogliotti I, Jimenez C, Varettoni M, Talaulikar D, Bagratuni T, Ferrante M, et al.
Leukemia
. 2022 Nov;
37(2):388-395.
PMID: 36435884
The diagnosis of Waldenström's macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, can be challenging due to the different forms of disease presentation. Furthermore, in recent years, WM has witnessed remarkable progress...
4.
Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, et al.
Blood Adv
. 2020 Sep;
4(17):4091-4101.
PMID: 32877524
For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20-based immunochemotherapy or develop relapsed or refractory disease, there remains a significant unmet clinical need for new therapeutic approaches to improve...
5.
Jelinek T, Popkova T, Duras J, Mihalyova J, Kascak M, Benkova K, et al.
Hematol Oncol
. 2020 Apr;
38(3):412-414.
PMID: 32323881
No abstract available.
6.
Hradska K, Kascak M, Hajek R, Jelinek T
Expert Rev Hematol
. 2020 Mar;
13(4):375-392.
PMID: 32116068
: One of the hallmarks of cancerogenesis is the ability of tumor cells to evade the immune system. They can achieve it by abusing inhibitory immune checkpoint pathways, which, under...
7.
Jelinek T, Adamusova L, Popkova T, Tvrda I, Smejkalova J, Simicek M, et al.
Bone Marrow Transplant
. 2018 Nov;
54(7):1107-1114.
PMID: 30459429
Cyclophosphamide (Cy) plus granulocyte-colony stimulating factor (G-CSF) is currently a standard regimen for hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma (MM). However, cytarabine (AraC) in intermediate doses...
8.
Jelinek T, Mihalyova J, Kascak M, Duras J, Popkova T, Benkova K, et al.
Am J Hematol
. 2018 Oct;
94(1):E35-E37.
PMID: 30370955
No abstract available.
9.
Growkova K, Kryukova E, Kufova Z, Filipova J, Sevcikova T, Rihova L, et al.
Eur J Haematol
. 2017 Sep;
99(6):469-478.
PMID: 28886236
Waldenström's macroglobulinemia (WM) is a complex disease characterized by apparent morphological heterogeneity within the malignant clonal cells representing a continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. At the...
10.
Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R
Immunology
. 2017 Jul;
152(3):357-371.
PMID: 28685821
The introduction of PD-1/PD-L1 pathway inhibitors is an important landmark in solid oncology with unprecedented practice-changing activity in various types of solid tumours. Among haematological malignancies, PD-1/PD-L1 inhibitors have been...